Literature DB >> 12182835

Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells.

Jörg Dobers1, Martin Zimmermann-Kordmann, Melanie Leddermann, Tina Schewe, Werner Reutter, Hua Fan.   

Abstract

The human dipeptidyl peptidase IV/CD26 (DPPIV/CD26) is a multifunctional type-II membrane bound glycoprotein. As a receptor of collagen I and fibronectin it mediates cell-cell and cell-matrix adhesion, and by interacting with extracellular adenosine deaminase and CD45 it is involved in regulatory and costimulatory events in the immune system. DPPIV/CD26 has a very distinct substrate specificity, and is potentially capable of truncating many cytokines, chemokines, and peptide hormones. In this study, we describe the overexpression, purification, and characterization of human DPPIV/CD26 in Spodoptera frugiperda (Sf9) cells, using the baculovirus system. Overexpression of DPPIV/CD26 was confirmed by measurement of its peptidase specificity, SDS-PAGE, and Western blot analyses. Expression rates were between 6.4 and 17.6 mg protein per liter suspension culture (1.5 x 10(9)cells). The N-linked oligosaccharide composition was examined and compared with that of mammalian cell-expressed DPPIV/CD26. Two-step purification by immunoaffinity chromatography and size-exclusion fast protein liquid chromatography (SE-FPLC) led to highly stable protein with significant peptidase activity. A subsequent gel filtration step on a Superdex 200 column yielded 2mg homogeneous dimeric DPPIV/CD26 (per liter insect cell culture) for crystallographic studies. Protein homogeneity was confirmed by silver staining of non-denaturating PAGE gels and by MALDI-TOF analysis of tryptic peptides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182835     DOI: 10.1016/s1046-5928(02)00043-8

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Monitoring of the effects of transfection with baculovirus on Sf9 cell line and expression of human dipeptidyl peptidase IV.

Authors:  Ozlem Ustün-Aytekin; Ismet Deliloğlu Gürhan; Kayoko Ohura; Teruko Imai; Gaye Ongen
Journal:  Cytotechnology       Date:  2013-05-29       Impact factor: 2.058

2.  N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.

Authors:  Kathleen Aertgeerts; Sheng Ye; Lihong Shi; Sridhar G Prasad; Darbi Witmer; Ellen Chi; Bi-Ching Sang; Robert A Wijnands; David R Webb; Ronald V Swanson
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

3.  Interaction of human dipeptidyl peptidase IV and human immunodeficiency virus type-1 transcription transactivator in Sf9 cells.

Authors:  Felista L Tansi; Véronique Blanchard; Markus Berger; Rudolf Tauber; Werner Reutter; Hua Fan
Journal:  Virol J       Date:  2010-10-13       Impact factor: 4.099

Review 4.  Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.

Authors:  Quan Gong; Sanjay Rajagopalan; Jixin Zhong
Journal:  Int J Cardiol       Date:  2015-06-27       Impact factor: 4.164

5.  A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2.

Authors:  Cecy R Xi; Arianna Di Fazio; Naveed Ahmed Nadvi; Karishma Patel; Michelle Sui Wen Xiang; Hui Emma Zhang; Chandrika Deshpande; Jason K K Low; Xiaonan Trixie Wang; Yiqian Chen; Christopher L D McMillan; Ariel Isaacs; Brenna Osborne; Ana Júlia Vieira de Ribeiro; Geoffrey W McCaughan; Joel P Mackay; W Bret Church; Mark D Gorrell
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.